Illumina supports the release of a landmark consensus on whole-genome sequencing in the diagnosis of genetic diseases in newborns
With the debut of the COVIDSeq Assay, smaller labs are participating in surveillance
How the Butantan Institute helped vaccinate the city of Serrana—and what they learned thereafter
Othram, Inc. and the NovaSeq help convert more cases from cold to solved
The collaboration will introduce VeriSeq™ NIPT Solution v2 in Southeast Asia
| Date | Publication | Title |
|---|---|---|
| Jul 28, 2021 | USA TODAY | Opinion: This new test for cancer could save your life. Here's why you can't get it. |
| Jul 13, 2021 | Reuters | Illumina, Grail deal faces full-scale EU antitrust probe – according to sources |
| Jul 6, 2021 | mLex | Illumina-Grail review sees EU regulator weighing matters of life and death |
| Jul 6, 2021 | USA TODAY | Opinion: Medical merger could improve cancer treatment for minorities. So why is FTC blocking it? |
| Jul 5, 2021 | Bloomberg | Is a Blood Test for Multiple Cancers Hope or Hype? |
At Illumina, we push boundaries. We think beyond the conventional. We dream big. With the energy of so many bright and accomplished people, the opportunities are endless.
Search for JobsIf you are a member of the media:
If you are not a member of the media, please visit Contact Us.
